Cataflam


Also found in: Thesaurus, Medical, Wikipedia.
Related to Cataflam: Voltaren
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Cataflam - a nonsteroidal anti-inflammatory drug (trade name Cataflam)
nonsteroidal anti-inflammatory, nonsteroidal anti-inflammatory drug, NSAID - an anti-inflammatory drug that does not contain steroids; "NSAIDs inhibit the activity of both Cox-1 and Cox-2 enzymes"
acetic acid, ethanoic acid - a colorless pungent liquid widely used in manufacturing plastics and pharmaceuticals
brand, brand name, marque, trade name - a name given to a product or service
References in periodicals archive ?
These manufacturers success is based on the strong exposure and traditional recognition of their most-established brands, which include Voltaren and Cataflam in the case of Novartis, and Bayer Aspirin, Dorival and Aleve in the case of Bayer.
KUWAIT, Feb 15 (KUNA) -- The anti-inflammatory drug, Cataflam, has not been rescinded by the Health Ministry, an official said on Sunday, denying rumours circulating on social media of its withdrawal from the Kuwaiti market.
But the ANA also mentions research that suggests an increased risk of cardiovascular events with conventional, nonselective COX-2 NSAIDs, such as ibuprofen and diclofenac (Cataflam, Voltaren).
Similarly, where Cataflam 50, made by a global company, will cost OMR7.100 for 20 tablets, the locally-made will cost only OMR3.350 for 20 tablets.
(4,13) Three of the 4 runners in the present study ingested NSAIDs during the 2010 Comrades Marathon: patients 2 and 4 ingested 2 and 7 Cataflam tablets respectively; and patient 3 ingested 3 Myprodol tablets.
Researchers analyzed the medical records of more than 1 million healthy Danish NSAID users (median age 39) to assess the cardiovascular risk of the traditional NSAIDs diclofenac (Cataflam, Voltaren), ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn), and the COX-2 inhibitors celecoxib (Celebrex) and rofecoxib (Vioxx, pulled from the market in 2004).
In the cohort study out of Denmark, the use of diclofenac (Cataflam, Voltaren) was associated with a 91 percent increase in the relative risk of a fatal heart attack or stroke in healthy adults.
Emil Loldrup Fosbol of Gentofte University Hospital in Hellerup, Denmark, and colleagues reported that patients in the study taking the nonselective NSAID didofenac (Voltaren, Cataflam) had a 91% increased risk of cardiovascular death, compared with patients with no NSMD history, and patients taking the selective cyclooxygenase2 (COX-2) inhibitor rofecoxib (Vioxx), which was withdrawn from the market in 2004 because of poor cardiovascular safety, had a 66% increased risk.